These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 24677538

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Standardizing drug adverse event reporting data.
    Wang L, Jiang G, Li D, Liu H.
    Stud Health Technol Inform; 2013; 192():1101. PubMed ID: 23920875
    [Abstract] [Full Text] [Related]

  • 5. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C, Hinomura Y, Kaneko M, Narukawa M.
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW, Hochberg AM, Pearson RK, Hauben M.
    Drug Saf; 2010 Dec 01; 33(12):1117-33. PubMed ID: 21077702
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
    Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y.
    Int J Med Sci; 2011 Dec 01; 8(4):332-8. PubMed ID: 21611115
    [Abstract] [Full Text] [Related]

  • 10. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
    Huang L, Zalkikar J, Tiwari RC.
    J Biopharm Stat; 2013 Dec 01; 23(1):178-200. PubMed ID: 23331230
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.
    Hochberg AM, Pearson RK, O'Hara DJ, Reisinger SJ.
    Drug Saf; 2009 Dec 01; 32(2):137-46. PubMed ID: 19236120
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Database size and power to detect safety signals in pharmacovigilance.
    Hammond IW, Gibbs TG, Seifert HA, Rich DS.
    Expert Opin Drug Saf; 2007 Nov 01; 6(6):713-21. PubMed ID: 17967160
    [Abstract] [Full Text] [Related]

  • 16. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
    Gandhi PK, Gentry WM, Bottorff MB.
    Pharmacotherapy; 2012 Oct 01; 32(10):902-9. PubMed ID: 23033229
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Data mining for signal detection of adverse event safety data.
    Chen HC, Tsong Y, Chen JJ.
    J Biopharm Stat; 2013 Oct 01; 23(1):146-60. PubMed ID: 23331228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.